ClinicalTrials.gg
CompletedNCT05526690Updated Aug 14, 2023

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

A Phase 1 interventional study of Metformin and CIN-107 in Hypertension, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry.
  • Registered 1 year 10 months after the study started (first participant enrolled Oct 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
15th of 18
27 · median 197
Started
2020
with 2 others
Phase 1
7 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 15th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 1, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a randomized, open-label, two-period, crossover Phase 1 to assess the impact of CIN-107 on the pharmacokinetics (PK) of metformin and the safety and tolerability of coadministration of CIN-107 and metformin as compared to metformin alone.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects between the ages of 18 and 55 years, inclusive, at Screening;
  • between 18 and 30 kg/m2, inclusive;
  • In good health based on medical/surgical and psychiatric history, physical examination, (ECG), vital signs (seated and orthostatic), and routine laboratory tests (serum chemistry, hematology, and urinalysis);
  • Normal renal function, defined as estimated ≥85 mL/min/1.73 m2 at Screening and Day -1;
  • Nonsmokers who have not used nicotine-containing products (ie, cigarettes, nicotine patch, nicotine chewing gum, or electronic cigarettes) for at least 6 months prior to Screening;

Exclusion criteria

Exclusion Criteria:

  • Actively participating in an experimental therapy study; received experimental therapy with a small molecule other than CIN-107 within 30 days of the first dose of study drug or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of the first dose of study drug or 5 half-lives, whichever is longer;
  • A personal or family history of long syndrome, Torsades de Pointes, other complex ventricular arrhythmias, or family history of sudden death;
  • History of, or current, arrhythmias, as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, sinus node dysfunction, or clinically significant heart block. Subjects with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded and may be discussed with the Medical Monitor for inclusion;
  • Prolonged QT interval corrected by Fridericia's formula (>450 msec);
  • Seated systolic blood pressure (BP) >140 mmHg and/or diastolic BP >90 mmHg or systolic BP \<90 mmHg and/or diastolic BP \<50 mmHg;
  • Postural tachycardia (ie, >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg upon standing);
  • Serum potassium > (ULN) of the reference range and serum sodium \<lower limit of normal of the reference range;
  • , alanine aminotransferase, or total values >1.2 × ULN;
  • Positive for antibody, virus antibody, surface antigen, or severe acute respiratory syndrome coronavirus 2 RNA;
  • Evidence or history of any clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, musculoskeletal, hepatic, psychiatric, neurologic, or allergic (including clinically significant or multiple drug allergies) disease; surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that has resolved or has been in remission for >5 years prior to Screening); or any condition that, in the Investigator's opinion, may confound study procedures or results, impact subject safety, or interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy allowed, cholecystectomy prohibited);
  • Typical consumption of ≥14 alcoholic drinks weekly; Note: 1 drink of alcohol is equivalent to ½ pint of beer (285 mL), 1 glass of spirits (25 mL), or 1 glass of wine (125 mL).
  • Surgical procedures within 4 weeks prior to Check-In (other than minor cosmetic surgery or minor dental procedures) or planned elective surgery during the treatment period;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    Treatment A: Immediate-release metformin

    Treatment A: single 1000 mg dose of immediate-release metformin Subjects will be randomly assigned to 1 of 2 sequences: AB or BA. * Treatment A: a single 1000 mg dose of immediate-release metformin; and * Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107. All study medication will be administered at 8:00 AM (±2 hours). There will be a minimum 10-day washout between administration of study drug in each treatment period.

    Drug: Metformin

  • Experimental
    Treatment B: Immediate-release metformin coadministered with a CIN-107

    Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107 Subjects will be randomly assigned to 1 of 2 sequences: AB or BA. * Treatment A: a single 1000 mg dose of immediate-release metformin; and * Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107. All study medication will be administered at 8:00 AM (±2 hours). For Treatment B, the dose of CIN-107 will be administered 2 hours prior to the dose of metformin. There will be a minimum 10-day washout between administration of study drug in each treatment period.

    Drug: Metformin · Drug: CIN-107

Interventions

  • 1000 mg dose of immediate-release metformin

  • 10 mg dose of CIN-107

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

    Time frame: Up to day 3

  2. Time to Cmax (Tmax)

    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

    Time frame: Up to day 3

  3. Area under the concentration-time curve (AUC) from time 0 to 72 hours

    This plasma PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites.

    Time frame: Up to day 3

  4. Maximum plasma concentration (Cmax) of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  5. Time to Cmax (Tmax) of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  6. AUC from time 0 to the time of last quantifiable plasma concentration of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  7. AUC from time 0 to infinity of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  8. Percent of AUC extrapolated of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  9. Terminal phase elimination half-life of metformin

    This plasma PK parameter will be determined for metformin.

    Time frame: Up to day 3

  10. Cumulative amount of metformin excreted in the urine (Ae) of metformin

    This urine PK parameter will be determined for metformin.

    Time frame: Up to day 3

  11. Renal clearance (calculated as Ae/AUC) of metformin

    This urine PK parameter will be determined for metformin.

    Time frame: Up to day 3

  12. Fraction of the dose excreted renally of metformin

    This urine PK parameter will be determined for metformin.

    Time frame: Up to day 3

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
08

References and documents

Publications

  • Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. Am J Cardiovasc Drugs. 2023 May;23(3):277-286. doi: 10.1007/s40256-023-00572-x. Epub 2023 Feb 15. PubMed 36790596 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Dec 2020, 1 month.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 2, 2022
StartActual
Oct 28, 2020
Primary completionActual
Dec 12, 2020
CompletionActual
Dec 12, 2020
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05526690
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Oct 28, 2020
Primary completion
Dec 12, 2020
Completion
Dec 12, 2020
Last update
Aug 14, 2023

Study contacts

Leela Leela Vrishabhendra, MD, MD
principal investigator · Medpace Clinical Pharmacology Unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion